Markets

Immutep Receives A$856,669 Cash Rebate From Australian Federal Government’s R&D Tax Incentive Program

Sep 30, 2026 · 08:06 AM ET· updated 1h ago

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash

Why It Matters

Immutep got about 857,000 Australian dollars back from the government for research spending. This extra cash helps the company keep working on new medicines without needing more money right now.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

IMMP4.80

+0.08 (+1.80%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.